Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Lapatinib (Primary) ; Letrozole (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms Neo-All-In
- 10 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Results of explorative mutational analysis (n=21) presented at the 41st European Society for Medical Oncology Congress.
- 19 Nov 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov record.